RecruitingNCT06212635
Hemostasis in Liver Cirrhosis and Hepatocellular Cancer
Novel Biomarkers for Evaluation of Hemostasis and Inflammation in Liver Cirrhosis
Sponsor
Region Stockholm
Enrollment
100 participants
Start Date
Dec 2, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Patients with decompensated liver cirrhosis
- years or older.
- Healthy individuals 18 years or older will serve as controls.
Exclusion Criteria6
- • Extrahepatic malignancy or recurrence of such within the last year.
- Diagnosis of non-cirrhotic coagulopathy, coagulation disorder or thrombophilia prior to inclusion.
- Diagnosis of hematological disease such as hematologic malignancies, non-cirrhotic thrombocytopenia or thrombocytosis, Polycytemia Vera, hemoglobinopathies
- Previous liver transplantation.
- Transfusions the last 7 days.
- Treatment with platelet inhibitors or anticoagulant except for prophylactic dosage of LMWH. If a prophylactic dose of LMWH has been used study sampling with addition of antiFXa must be taken \>12 hours after the last injection.
Interventions
DIAGNOSTIC_TESTT-TAS
Blood test, laboratory assays
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06212635